UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 166

Sortiert nach

Selexipag in pregnancy and pulmonary arterial hypertension

IHJ cardiovascular case reports, 2023-01, Vol.7 (1), p.33-35

2023

Volltextzugriff (PDF)

Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension

Chest, 2021-07, Vol.160 (1), p.277-286

2021

Volltextzugriff (PDF)

Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies

Journal of clinical pharmacology, 2017-05, Vol.57 (5), p.547-557

2017

Volltextzugriff (PDF)

Selexipag improves Lipopolysaccharide-induced ARDS on C57BL/6 mice by modulating the cAMP/PKA and cAMP/Epac1 signaling pathways

Biological and Pharmaceutical Bulletin, 2022, pp.b21-01057

2022

Volltextzugriff (PDF)

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

European heart journal, 2022-10, Vol.43 (38), p.3618-3731

2022

Volltextzugriff (PDF)

Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension

Chest, 2023-02, Vol.163 (2), p.407-418

2023

Volltextzugriff (PDF)

Selexipag for the Treatment of Pulmonary Arterial Hypertension

The New England journal of medicine, 2015-12, Vol.373 (26), p.2522-2533

2015

Volltextzugriff (PDF)

A novel HPLC method for selexipag in human plasma and application to a prototype pharmacokinetic study

Acta chromatographica, 2024-09, Vol.36 (3), p.273-278

2024

Volltextzugriff (PDF)

Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2021-10, Vol.78 (14), p.1393-1403

2021

Volltextzugriff (PDF)

Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension

Orphanet journal of rare diseases, 2018-12, Vol.13 (1)

2018

Volltextzugriff (PDF)

Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study

Chest, 2021-07, Vol.160 (1), p.277-286

2021

Volltextzugriff (PDF)

Nanosuspensions of Selexipag: Formulation, Characterization, and in vitro Evaluation

Iraqi journal of pharmaceutical sciences, 2021-06, Vol.30 (1), p.144-153

2021

Volltextzugriff (PDF)

A real-world analysis of safety profile of selexipag by using FDA adverse Event Reporting System (FAERS)

Expert opinion on drug safety, 2024-07, Vol.23 (7), p.937-948

2024

Volltextzugriff (PDF)

The selective PGI.sub.2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats

PloS one, 2020-10, Vol.15 (10), p.e0240692

2020

Volltextzugriff (PDF)

Assessment of environmental impact of a novel stability-indicating RP-HPLC method and reported methods for the determination of selexipag in bulk and dosage form: A comparative study using different greenness assessment tools

Microchemical journal, 2023-02, Vol.185, p.108256, Article 108256

2023

Volltextzugriff (PDF)

Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects

British journal of clinical pharmacology, 2021-01, Vol.87 (1), p.119-128

2021

Volltextzugriff (PDF)

Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years

Molecules (Basel, Switzerland), 2020-02, Vol.25 (4), p.884

2020

Volltextzugriff (PDF)

Group 5 Pulmonary Hypertension Associated With T-Cell Large Granular Lymphocytic Leukemia

Chest, 2024-07, Vol.166 (1), p.e1-e3

2024

Volltextzugriff (PDF)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration

Frontiers in pediatrics, 2023-08, Vol.11, p.1275389-1275389

2023

Volltextzugriff (PDF)

Selexipag for patients with pulmonary hypertension associated with lung disease: A preliminary study

Respiratory investigation, 2024-09, Vol.62 (5), p.850-855

2024

Volltextzugriff (PDF)

Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series

American journal of health-system pharmacy, 2018-12, Vol.75 (23), p.1877-1881

2018

Volltextzugriff (PDF)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

European journal of heart failure, 2022-01, Vol.24 (1), p.205-214

2022

Volltextzugriff (PDF)

Prodrugs – Recent approvals and a glimpse of the pipeline

European journal of pharmaceutical sciences, 2017-11, Vol.109, p.146-161

2017

Volltextzugriff (PDF)

Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy

Journal of cardiology cases, 2022-07, Vol.26 (1), p.42-45

2022

Volltextzugriff (PDF)

Effectiveness of a Prostacyclin IP Receptor Agonist in Patients With Pulmonary Arterial Hypertension in the Real-world Andalusian Setting: The RAMPHA Study

Clinical therapeutics, 2024-06, Vol.46 (6), p.509-514

2024

Volltextzugriff (PDF)

1 – 25 von 166

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(140)
Mit Volltextzugriff
(125)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Selexipag
(160)
Science & Technology
(120)
Life Sciences & Biomedicine
(117)
Pulmonary Arterial Hypertension
(72)
Pulmonary Hypertension
(67)
Humans
(61)
Pharmacology & Pharmacy
(45)
Prostacyclin
(39)
Cardiovascular System & Cardiology
(35)
Hypertension, Pulmonary - Drug Therapy
(34)
Cardiac & Cardiovascular Systems
(33)
Treprostinil
(33)
Respiratory System
(29)
Hypertension
(28)
Male
(25)
Macitentan
(21)
Adult
(20)
Middle Aged
(19)
Patients
(19)
Acetamides - Administration & Dosage
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Selexipag in pregnancy and pulmonary arterial hypertension

Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension

Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies

Selexipag improves Lipopolysaccharide-induced ARDS on C57BL/6 mice by modulating the cAMP/PKA and cAMP/Epac1 signaling pathways

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension

Selexipag for the Treatment of Pulmonary Arterial Hypertension

A novel HPLC method for selexipag in human plasma and application to a prototype pharmacokinetic study

Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension

Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study

Nanosuspensions of Selexipag: Formulation, Characterization, and in vitro Evaluation

A real-world analysis of safety profile of selexipag by using FDA adverse Event Reporting System (FAERS)

The selective PGI.sub.2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats

Assessment of environmental impact of a novel stability-indicating RP-HPLC method and reported methods for the determination of selexipag in bulk and dosage form: A comparative study using different greenness assessment tools

Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects

Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years

Group 5 Pulmonary Hypertension Associated With T-Cell Large Granular Lymphocytic Leukemia

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration

Selexipag for patients with pulmonary hypertension associated with lung disease: A preliminary study

Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

Prodrugs – Recent approvals and a glimpse of the pipeline

Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy

Effectiveness of a Prostacyclin IP Receptor Agonist in Patients With Pulmonary Arterial Hypertension in the Real-world Andalusian Setting: The RAMPHA Study

Suchergebnisse filtern